Skip to main content

NCT03880019 - Olaparib and Temozolomide in Treating Patients With Advanced, Metastatic, or Unresectable Uterine Leiomyosarcoma

Brief Title
Olaparib and Temozolomide in Treating Patients With Advanced, Metastatic, or Unresectable Uterine Leiomyosarcoma
Protocol ID
NCT03880019
Brief Summary
Conditions:   Stage III Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IV Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8
Interventions:   Drug: Olaparib;   Drug: Temozolomide
Sponsor:   National Cancer Institute (NCI)
Recruiting
Pub Date: 
Tuesday, March 19, 2019 - 9:00am
Study URL: 
http://clinicaltrials.gov/ct2/show/NCT03880019?term=genomics%20DNA&%3Brecrs=abc